During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use ...

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

The investigators retrospectively reviewed records for 55 patients who received perioperative therapy for RCC, 28 who received IO/TKI, and 27 who received IO/IO. The two groups were similar with ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

Despite these excellent results, questions still remain whether the use of oral EGFR-TKI therapy alone is sufficient, or if certain patients may still require upfront radiation in combination with ...

Panelists discuss how chronic myeloid leukemia (CML) treatment has evolved over the past 5 years, highlighting advancements in tyrosine kinase inhibitor (TKI) therapy, improved adverse effect ...

Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received nationwide Medicare coverage ...

J&J meanwhile is also exploring the use of Rybrevant in patients who have failed TKI therapy and only have chemo as an option. The bispecific antibody looks set to have the exon 20 market to its ...